Shuguang Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shuguang Tan has a total of 460 co-authors. Here are the top co-authors by number of shared publications:
- George Fu Gao
Strategic Pandemic Preparedness Action and Research Center (SPARC), Guangzhou National Laboratory
31 shared publications Jianxun Qi
Institute of Microbiology, Chinese Academy of Sciences (CAS)
15 shared publicationsYan Chai
CAS Key Laboratory of Pathogen Microbiology and Immunology Institute of Microbiology Chinese Academy of Sciences Beijing 100101 China
15 shared publicationsJinghua Yan
CAS Key Laboratory of Microbial Physiological and Metabolic Engineering Institute of Microbiology Chinese Academy of Sciences Beijing China
11 shared publicationsJun Liu
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China
11 shared publicationsGeorge F. Gao
Institute of Microbiology, Chinese Academy of Sciences (CAS)
8 shared publications
Latest Publications
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy
T cell receptor (TCR)–based immunotherapy is limited by tumor antigen heterogeneity, which frequently leads to relapse. We developed a bispecific TCR-JANUS engager that functions synergistically with TCR engineered T cells (TCR-T). In contrast to conventional T cell engagers targeting CD3, TCR-JANUS engages both the variable region of a transgenic TCR (TRBV) and a tumor surface antigen. Using a model system targeting a humanized KRAS-G12V–specific TCR and trophoblast cell surface antigen 2 (Trop2), we show that TCR-JANUS effectively redirects TCR-T cells to lyse Trop2-expressing tumor cells while preserving intrinsic specificity toward the cognate pHLA target, thereby enabling simultaneous dual-antigen recognition. In heterogeneous tumor models, the combination of TCR-JANUS with TCR-T cells, an integrated system termed T Cell Dual Arsenal Recon, potently suppressed tumor growth by clearing antigenically divergent populations. Moreover, TCR-JANUS maintained enhanced T cell functionality with reduced exhaustion compared to anti-CD3–based engagers upon chronic stimulation. Together, this approach offers a targeted and durable strategy to overcome antigenic heterogeneity, expanding the clinical prospects of TCR-T cell therapy for solid tumors.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy
T cell receptor (TCR)–based immunotherapy is limited by tumor antigen heterogeneity, which frequently leads to relapse. We developed a bispecific TCR-JANUS engager that functions synergistically with TCR engineered T cells (TCR-T). In contrast to conventional T cell engagers targeting CD3, TCR-JANUS engages both the variable region of a transgenic TCR (TRBV) and a tumor surface antigen. Using a model system targeting a humanized KRAS-G12V–specific TCR and trophoblast cell surface antigen 2 (Trop2), we show that TCR-JANUS effectively redirects TCR-T cells to lyse Trop2-expressing tumor cells while preserving intrinsic specificity toward the cognate pHLA target, thereby enabling simultaneous dual-antigen recognition. In heterogeneous tumor models, the combination of TCR-JANUS with TCR-T cells, an integrated system termed T Cell Dual Arsenal Recon, potently suppressed tumor growth by clearing antigenically divergent populations. Moreover, TCR-JANUS maintained enhanced T cell functionality with reduced exhaustion compared to anti-CD3–based engagers upon chronic stimulation. Together, this approach offers a targeted and durable strategy to overcome antigenic heterogeneity, expanding the clinical prospects of TCR-T cell therapy for solid tumors.
- Open Access
- 3 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 214
Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases
Human papillomavirus (HPV)-associated cervical diseases pose significant health risks to women worldwide. Current clinical interventions face challenges in achieving complete viral clearance and controlling disease progression, with limited efficacy and recurrence risks. To address this unmet need, we developed an innovative nanovaccine (HM-NPs@LP) designed to codeliver tumor cell membranes (TMs), bacterial cytoplasmic membranes (EMs), and HPV16 long peptides (LP) through PLGA nanoparticles to elicit antitumor immunity. HPV16 E5/E6/E7 LP and TM provide individualized broad-spectrum antigen repertoires, including tumor-specific and tumor-associated antigens. EMs serve as natural adjuvants to enhance immunogenicity. The resulting nanovaccine demonstrates uniform nanoparticles (177 nm) with excellent stability and biosafety. In vitro, HM-NPs@LP exhibited efficient uptake by bone marrow-derived dendritic cells (BMDCs), which in turn promoted DC maturation and strengthened tumor-specific T-cell responses. In vivo studies in murine models demonstrate that HM-NPs@LP preferentially accumulate in lymph nodes and elicit potent tumor suppression. Furthermore, this vaccination induces durable immune memory to prevent tumor recurrence with minimal systemic toxicity. Additionally, humanized HLA-A*02:01 transgenic mice mirror these therapeutic outcomes. Synergy with taxane-platinum (TP) chemotherapy and anti-PD-1 immunotherapy further augments tumor regression. Overall, the scalable production, biosafety, and adaptability for personalized immunotherapy position this nanovaccine platform as a promising therapeutic strategy for the treatment of HPV-related cervical diseases and potentially other malignancies.
- 3 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 214
Open AccessInnovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases
Human papillomavirus (HPV)-associated cervical diseases pose significant health risks to women worldwide. Current clinical interventions face challenges in achieving complete viral clearance and controlling disease progression, with limited efficacy and recurrence risks. To address this unmet need, we developed an innovative nanovaccine (HM-NPs@LP) designed to codeliver tumor cell membranes (TMs), bacterial cytoplasmic membranes (EMs), and HPV16 long peptides (LP) through PLGA nanoparticles to elicit antitumor immunity. HPV16 E5/E6/E7 LP and TM provide individualized broad-spectrum antigen repertoires, including tumor-specific and tumor-associated antigens. EMs serve as natural adjuvants to enhance immunogenicity. The resulting nanovaccine demonstrates uniform nanoparticles (177 nm) with excellent stability and biosafety. In vitro, HM-NPs@LP exhibited efficient uptake by bone marrow-derived dendritic cells (BMDCs), which in turn promoted DC maturation and strengthened tumor-specific T-cell responses. In vivo studies in murine models demonstrate that HM-NPs@LP preferentially accumulate in lymph nodes and elicit potent tumor suppression. Furthermore, this vaccination induces durable immune memory to prevent tumor recurrence with minimal systemic toxicity. Additionally, humanized HLA-A*02:01 transgenic mice mirror these therapeutic outcomes. Synergy with taxane-platinum (TP) chemotherapy and anti-PD-1 immunotherapy further augments tumor regression. Overall, the scalable production, biosafety, and adaptability for personalized immunotherapy position this nanovaccine platform as a promising therapeutic strategy for the treatment of HPV-related cervical diseases and potentially other malignancies.
- Open Access
- 27 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (22)
Lactylation of PD-L1 by a lactyltransferase HAT1 dictates its protein stability and tumor immune evasion
Lysine lactylation regulates protein fate and function across diverse biological processes. While PD-L1 has been widely studied posttranslationally, the role of its lactylation and the responsible enzyme have remained poorly studied. Here, we identify histone acetyltransferase 1 (HAT1) as a lactyltransferase that catalyzes programmed cell death ligand 1 (PD-L1) lactylation at residues K75 and K178 within its extracellular domain, thereby enhancing PD-L1 stability. Mechanistically, this glycosylation-dependent modification protects PD-L1 from endoplasmic reticulum (ER)-associated degradation and promotes ER-to-Golgi trafficking. Targeting PD-L1 lactylation by HAT1 knockdown, mutation of the lactylation sites or HAT1-PD-L1-interferring peptides suppresses tumor progression and enhances anti-PD-1 therapy efficacy. Clinically, lactylated PD-L1 strongly correlates with tumor progression. Together, these findings establish HAT1-mediated PD-L1 lactylation as a key mechanism of immune evasion and suggest that targeting this pathway could improve cancer immunotherapy outcomes.
- 27 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (22)
Open AccessLactylation of PD-L1 by a lactyltransferase HAT1 dictates its protein stability and tumor immune evasion
Lysine lactylation regulates protein fate and function across diverse biological processes. While PD-L1 has been widely studied posttranslationally, the role of its lactylation and the responsible enzyme have remained poorly studied. Here, we identify histone acetyltransferase 1 (HAT1) as a lactyltransferase that catalyzes programmed cell death ligand 1 (PD-L1) lactylation at residues K75 and K178 within its extracellular domain, thereby enhancing PD-L1 stability. Mechanistically, this glycosylation-dependent modification protects PD-L1 from endoplasmic reticulum (ER)-associated degradation and promotes ER-to-Golgi trafficking. Targeting PD-L1 lactylation by HAT1 knockdown, mutation of the lactylation sites or HAT1-PD-L1-interferring peptides suppresses tumor progression and enhances anti-PD-1 therapy efficacy. Clinically, lactylated PD-L1 strongly correlates with tumor progression. Together, these findings establish HAT1-mediated PD-L1 lactylation as a key mechanism of immune evasion and suggest that targeting this pathway could improve cancer immunotherapy outcomes.
- Open Access
- 1 January 2026
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 12 (2) , 100-115
Rapid identification of antigen-specific TCRs for cancer immunotherapy
T cell receptors (TCRs) can recognize peptides presented by major histocompatibility complex (MHC) molecules, referred to as HLA in humans, which enables the targeted eradication of tumor cells expressing specific antigens. In recent years, TCR-engineered T cell (TCR-T) cell therapy has demonstrated substantial advancements in clinical trials targeting solid tumors. Notably, in August 2024, the U.S. FDA approved the first TCR-T drug for the treatment of advanced synovial sarcoma, representing a pivotal milestone in the field. For the development of TCR-T therapy, identifying tumor-associated antigen epitopes and high-functional TCRs are critical. Here, we present a comprehensive protocol outlining the process of identification of immunogenic epitopes and the efficient screening of antigen-specific TCRs from HLA transgenic mice. Additionally, the protocol encompasses methodologies for TCR-T cell preparation and their functional evaluation in vitro. These approaches provide a robust framework for advancing the development of tumor-specific TCRs and fostering the clinical translation of TCR-T therapies.
- 1 January 2026
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 12 (2) , 100-115
Open AccessRapid identification of antigen-specific TCRs for cancer immunotherapy
T cell receptors (TCRs) can recognize peptides presented by major histocompatibility complex (MHC) molecules, referred to as HLA in humans, which enables the targeted eradication of tumor cells expressing specific antigens. In recent years, TCR-engineered T cell (TCR-T) cell therapy has demonstrated substantial advancements in clinical trials targeting solid tumors. Notably, in August 2024, the U.S. FDA approved the first TCR-T drug for the treatment of advanced synovial sarcoma, representing a pivotal milestone in the field. For the development of TCR-T therapy, identifying tumor-associated antigen epitopes and high-functional TCRs are critical. Here, we present a comprehensive protocol outlining the process of identification of immunogenic epitopes and the efficient screening of antigen-specific TCRs from HLA transgenic mice. Additionally, the protocol encompasses methodologies for TCR-T cell preparation and their functional evaluation in vitro. These approaches provide a robust framework for advancing the development of tumor-specific TCRs and fostering the clinical translation of TCR-T therapies.
- Open Access
- 5 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (31) , e00181
An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy
T cell receptor (TCR) based immunotherapy is an attractive strategy to target a wide range of intra‐tumoral antigens and elicit robust tumor cytotoxicity. However, engineering soluble TCR engagers that preserve physiological affinity is crucial for universal TCR drug development, yet remains challenging. In the present study, multiple TCR engagers featuring diverse architectures based on the KRAS‐G12V specific 1–2C TCR in the context of HLA‐A*11:01 is designed and evaluated. Notably, a soluble tandem double single‐chain TCR (STanD‐scTCR) engager, comprising two repeated single‐chain variable fragment (scFv) TCRs, exhibit enhanced binding avidity and potent T‐cell activation. Through site‐directed mutagenesis, T96F mutation (T96F‐TCR) within the TCR β chain is identified, which substantially augment T cell reactivity while maintaining physiological affinity and minimizing off‐target cross‐reactivity. The T96F‐mutated STanD‐scTCR engager demonstrates improved antigen sensitivity, promotes multi‐functional T‐cell responses, and facilitates immune synapse formation between T cells and target cells. In a xenograft tumor model harboring the KRAS‐G12V mutation, the TCR engager displays substantial tumor suppression efficacy. These findings underscore the therapeutic potential of 1–2C STanD‐scTCR engage in targeting KRAS‐G12V mutations in the context of HLA‐A*11:01. Furthermore, the engineering strategies employ in the development of STanD‐scTCR engager provide an invaluable for future designs of TCR engager drugs.
- 5 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (31) , e00181
Open AccessAn Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy
T cell receptor (TCR) based immunotherapy is an attractive strategy to target a wide range of intra‐tumoral antigens and elicit robust tumor cytotoxicity. However, engineering soluble TCR engagers that preserve physiological affinity is crucial for universal TCR drug development, yet remains challenging. In the present study, multiple TCR engagers featuring diverse architectures based on the KRAS‐G12V specific 1–2C TCR in the context of HLA‐A*11:01 is designed and evaluated. Notably, a soluble tandem double single‐chain TCR (STanD‐scTCR) engager, comprising two repeated single‐chain variable fragment (scFv) TCRs, exhibit enhanced binding avidity and potent T‐cell activation. Through site‐directed mutagenesis, T96F mutation (T96F‐TCR) within the TCR β chain is identified, which substantially augment T cell reactivity while maintaining physiological affinity and minimizing off‐target cross‐reactivity. The T96F‐mutated STanD‐scTCR engager demonstrates improved antigen sensitivity, promotes multi‐functional T‐cell responses, and facilitates immune synapse formation between T cells and target cells. In a xenograft tumor model harboring the KRAS‐G12V mutation, the TCR engager displays substantial tumor suppression efficacy. These findings underscore the therapeutic potential of 1–2C STanD‐scTCR engage in targeting KRAS‐G12V mutations in the context of HLA‐A*11:01. Furthermore, the engineering strategies employ in the development of STanD‐scTCR engager provide an invaluable for future designs of TCR engager drugs.
- Top Cited PapersOpen Access
- 28 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (20) , e2415196
Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC
Cancer‐associated fibroblasts (CAFs) play a crucial role in the progression of pancreatic ductal adenocarcinoma (PDAC). Here, integrated single‐cell RNA sequencing analysis is utilized to comprehensively map CAFs in the human PDAC tumor microenvironment (TME). Normal fibroblasts (NFs) and nine distinct CAF subtypes are identified including newly identified CAF subtypes, CDCP1 + FTL + CAFs, transitional CAFs (tCAFs), interferon simulated genes (ISG) + myofibroblastic CAFs (myCAFs), and proliferative CAFs (pCAFs). CDCP1 + FTL + CAFs, pCAFs, and ISG + myCAFs are associated with unfavorable clinical outcomes. CDCP1 + FTL + CAFs exhibit enhanced glycolysis and iron metabolism, resisting ferroptosis. The antigen‐presenting CAFs (apCAFs) show high heterogeneity, consisting of multiple subtypes expressing distinct immune cell signatures. The CAF subtypes display differentiation plasticity, transitioning from early normal‐like CAFs (nCAFs) to inflammatory CAFs (iCAFs) and myCAFs, ultimately leading to more invasive pCAFs. AP‐1 family members FOS and JUN regulate the malignant phenotype conversion of NFs to nCAFs, while transforming growth factor‐β (TGFβ) and interferon‐γ (IFNγ) signals trigger the interconversion between classic myCAFs and iCAFs, respectively. A close interaction between CAFs and myeloid cells (especially neutrophils) is further observed in PDAC‐TME, mainly mediated by CXCR4‐CXCL12 chemotaxis. This work depicts a detailed CAF map and its dynamic interconvertible shift, providing important insights for combined targeted CAFs therapy.
- 28 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (20) , e2415196
Top Cited PapersOpen AccessTranscriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC
Cancer‐associated fibroblasts (CAFs) play a crucial role in the progression of pancreatic ductal adenocarcinoma (PDAC). Here, integrated single‐cell RNA sequencing analysis is utilized to comprehensively map CAFs in the human PDAC tumor microenvironment (TME). Normal fibroblasts (NFs) and nine distinct CAF subtypes are identified including newly identified CAF subtypes, CDCP1 + FTL + CAFs, transitional CAFs (tCAFs), interferon simulated genes (ISG) + myofibroblastic CAFs (myCAFs), and proliferative CAFs (pCAFs). CDCP1 + FTL + CAFs, pCAFs, and ISG + myCAFs are associated with unfavorable clinical outcomes. CDCP1 + FTL + CAFs exhibit enhanced glycolysis and iron metabolism, resisting ferroptosis. The antigen‐presenting CAFs (apCAFs) show high heterogeneity, consisting of multiple subtypes expressing distinct immune cell signatures. The CAF subtypes display differentiation plasticity, transitioning from early normal‐like CAFs (nCAFs) to inflammatory CAFs (iCAFs) and myCAFs, ultimately leading to more invasive pCAFs. AP‐1 family members FOS and JUN regulate the malignant phenotype conversion of NFs to nCAFs, while transforming growth factor‐β (TGFβ) and interferon‐γ (IFNγ) signals trigger the interconversion between classic myCAFs and iCAFs, respectively. A close interaction between CAFs and myeloid cells (especially neutrophils) is further observed in PDAC‐TME, mainly mediated by CXCR4‐CXCL12 chemotaxis. This work depicts a detailed CAF map and its dynamic interconvertible shift, providing important insights for combined targeted CAFs therapy.
- Top Cited Papers
- 28 January 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (2) , 265-278
T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots
Although antibody escape is observed in emerging severe acute respiratory syndrome coronavirus 2 variants, T cell escape, especially after the global circulation of BA.2.86/JN.1, is unexplored. Here we demonstrate that T cell evasion exists in epitope hotspots spanning BA.2.86/JN.1 mutations. The newly emerging Q229K at this conserved nucleocapsid protein site impairs HLA-A2 epitope hotspot recognition. The association between HLA-A24 convalescents and T cell immune escape points to the spike (S) protein epitope S448–456NYNYLYRLF, with multiple mutations from Delta to JN.1, including L452Q, L452R, F456L, N450D and L452W, and N450D, L452W and L455S. A cliff drop of immune responses was observed for S448–456NYNYRYRLF (Delta/BA.5.2) and S448–456NYDYWYRSF (JN.1), but with immune preservation of S448–456NYDYWYRLF (BA.2.86). Structural analyses showed that hydrophobicity exposure determines the pronounced escape of L452R and L455S mutants, which was further confirmed by T cell receptor binding. This study highlights the characteristics and molecular mechanisms of the T cell immune escape for JN.1 and provides new insights into understanding the dominant circulation of variants, from the viewpoint of cytotoxic T cell evasion.
- 28 January 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (2) , 265-278
Top Cited PapersT cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots
Although antibody escape is observed in emerging severe acute respiratory syndrome coronavirus 2 variants, T cell escape, especially after the global circulation of BA.2.86/JN.1, is unexplored. Here we demonstrate that T cell evasion exists in epitope hotspots spanning BA.2.86/JN.1 mutations. The newly emerging Q229K at this conserved nucleocapsid protein site impairs HLA-A2 epitope hotspot recognition. The association between HLA-A24 convalescents and T cell immune escape points to the spike (S) protein epitope S448–456NYNYLYRLF, with multiple mutations from Delta to JN.1, including L452Q, L452R, F456L, N450D and L452W, and N450D, L452W and L455S. A cliff drop of immune responses was observed for S448–456NYNYRYRLF (Delta/BA.5.2) and S448–456NYDYWYRSF (JN.1), but with immune preservation of S448–456NYDYWYRLF (BA.2.86). Structural analyses showed that hydrophobicity exposure determines the pronounced escape of L452R and L455S mutants, which was further confirmed by T cell receptor binding. This study highlights the characteristics and molecular mechanisms of the T cell immune escape for JN.1 and provides new insights into understanding the dominant circulation of variants, from the viewpoint of cytotoxic T cell evasion.
- 29 May 2024
- Published by Elsevier in Science Bulletin
- Vol. 70 (1) , 42-46
Single-cell multi-omics analysis revealing immune features of inactivated COVID-19 vaccination in systemic lupus erythematosus patients
- 29 May 2024
- Published by Elsevier in Science Bulletin
- Vol. 70 (1) , 42-46
Single-cell multi-omics analysis revealing immune features of inactivated COVID-19 vaccination in systemic lupus erythematosus patients
- 24 May 2024
- Published by Elsevier in Molecular Immunology
- Vol. 171, 56-65
Identification of HPV-E7 specific TCRs for tumor immunotherapy
- 24 May 2024
- Published by Elsevier in Molecular Immunology
- Vol. 171, 56-65
Identification of HPV-E7 specific TCRs for tumor immunotherapy
- Open Access
- 12 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells. In the present study, we identify two TCRs specific for the 9-mer KRAS-G12V mutant neoantigen in the context of HLA-A*11:01. The TCR-T cells are constructed and display cytokine secretion and cytotoxicity upon co-culturing with varied tumor cells expressing the KRAS-G12V mutation. Moreover, 1-2C TCR-T cells show anti-tumor activity in preclinical models in female mice. The 9-mer KRAS-G12V mutant peptide exhibits a distinct conformation from the 9-mer wildtype peptide and its 10-mer counterparts. Specific recognition of the G12V mutant by TCR depends both on distinct conformation from wildtype peptide and on direct interaction with residues from TCRs. Our study reveals the mechanisms of presentation and TCR recognition of KRAS-G12V mutant peptide and describes TCRs with therapeutic potency for tumor immunotherapy.
- 12 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Open AccessKRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells. In the present study, we identify two TCRs specific for the 9-mer KRAS-G12V mutant neoantigen in the context of HLA-A*11:01. The TCR-T cells are constructed and display cytokine secretion and cytotoxicity upon co-culturing with varied tumor cells expressing the KRAS-G12V mutation. Moreover, 1-2C TCR-T cells show anti-tumor activity in preclinical models in female mice. The 9-mer KRAS-G12V mutant peptide exhibits a distinct conformation from the 9-mer wildtype peptide and its 10-mer counterparts. Specific recognition of the G12V mutant by TCR depends both on distinct conformation from wildtype peptide and on direct interaction with residues from TCRs. Our study reveals the mechanisms of presentation and TCR recognition of KRAS-G12V mutant peptide and describes TCRs with therapeutic potency for tumor immunotherapy.